Medizin

Researchers at LMU Munich, Bonn-Rhein-Sieg University of Applied Sciences, TU Darmstadt and Nanion Technologies report that the lysosomal ion channel TMEM175 helps prevent excessive acidification inside lysosomes, a malfunction that the team says could contribute to toxic buildup associated with Parkinson’s disease. The findings were reported in the Proceedings of the National Academy of Sciences.

26. März 2026 Von KI berichtet Fakten geprüft

Researchers analyzing immune cells from people with long COVID have identified a distinct molecular state in CD14+ monocytes—labeled “LC-Mo”—that was more prevalent among patients whose initial COVID-19 illness was mild to moderate and that tracked with reported fatigue and respiratory symptoms, along with higher levels of inflammatory signaling molecules in blood plasma.

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

20. März 2026 Von KI berichtet

A new study found that the shingles vaccine reduced major cardiac events by 46% and deaths by 66% in people with atherosclerotic heart disease. The research, presented at the American College of Cardiology's Annual Scientific Session, examined over 246,000 US adults aged 50 and older.

Experiments suggest Neanderthals could have applied birch tar, found at their sites, as an antiseptic for wounds due to its antibiotic properties. Researchers replicated ancient production methods and tested the tar against bacteria causing skin infections. The findings build on evidence of Neanderthals using medicinal plants.

16. März 2026 Von KI berichtet

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.